Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
Standard
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. / Bacher, Ulrike; Kern, Wolfgang; Alpermann, Tamara; Schnittger, Susanne; Haferlach, Claudia; Haferlach, Torsten.
in: LEUKEMIA RES, Jahrgang 36, Nr. 7, 7, 2012, S. 826-831.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
AU - Bacher, Ulrike
AU - Kern, Wolfgang
AU - Alpermann, Tamara
AU - Schnittger, Susanne
AU - Haferlach, Claudia
AU - Haferlach, Torsten
PY - 2012
Y1 - 2012
N2 - In 2008, the WHO combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (ring sideroblasts ? 15%). We studied the clinical impact and genetic background of RARS, RCMD, and RCMD-RS in 1082 patients. Good karyotypes (IPSS) were similarly frequent in RARS, RCMD, and RCMD-RS. 2-year overall survival (OS) rates were similar in RARS, RCMD, and RCMD-RS (85.9%/89.0%/91.7%; n.s.). The 2-year OS rate was better in good than intermediate or poor karyotypes (p<0.001). These results support to combine RCMD and RCMD-RS as performed by WHO and emphasize the prognostic power of cytogenetic criteria for these MDS subtypes.
AB - In 2008, the WHO combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (ring sideroblasts ? 15%). We studied the clinical impact and genetic background of RARS, RCMD, and RCMD-RS in 1082 patients. Good karyotypes (IPSS) were similarly frequent in RARS, RCMD, and RCMD-RS. 2-year overall survival (OS) rates were similar in RARS, RCMD, and RCMD-RS (85.9%/89.0%/91.7%; n.s.). The 2-year OS rate was better in good than intermediate or poor karyotypes (p<0.001). These results support to combine RCMD and RCMD-RS as performed by WHO and emphasize the prognostic power of cytogenetic criteria for these MDS subtypes.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Young Adult
KW - Cohort Studies
KW - Prognosis
KW - Survival Analysis
KW - Anemia, Refractory/diagnosis/epidemiology/genetics/mortality
KW - Anemia, Sideroblastic/diagnosis/epidemiology/genetics/mortality
KW - Cytogenetics/methods
KW - Myelodysplastic Syndromes/classification/diagnosis/genetics/mortality
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Young Adult
KW - Cohort Studies
KW - Prognosis
KW - Survival Analysis
KW - Anemia, Refractory/diagnosis/epidemiology/genetics/mortality
KW - Anemia, Sideroblastic/diagnosis/epidemiology/genetics/mortality
KW - Cytogenetics/methods
KW - Myelodysplastic Syndromes/classification/diagnosis/genetics/mortality
M3 - SCORING: Journal article
VL - 36
SP - 826
EP - 831
JO - LEUKEMIA RES
JF - LEUKEMIA RES
SN - 0145-2126
IS - 7
M1 - 7
ER -